851936-86-2Relevant articles and documents
BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR
-
Paragraph 00153, (2021/11/26)
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR
-
Paragraph 0072, (2020/08/19)
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitinization of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor
Li, Huifang,Ban, Fuqiang,Dalal, Kush,Leblanc, Eric,Frewin, Kate,Ma, Dennis,Adomat, Hans,Rennie, Paul S.,Cherkasov, Artem
supporting information, p. 6458 - 6467 (2014/10/15)
The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.
TRPV1 Antagonists
-
Paragraph 0346, (2013/06/28)
Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
TRPV1 ANTAGONISTS
-
Page/Page column 114, (2010/04/30)
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
TRPV1 ANTAGONISTS
-
Page/Page column 112, (2010/04/30)
Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
-
Page/Page column 42-43, (2008/06/13)
Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
Structure-reactivity correlations for reactions of substituted phenolate anions with acetate and formate esters
Stefanidis, Dimitrios,Cho, Sayeon,Dhe-Paganon, Sirano,Jencks, William P.
, p. 1650 - 1656 (2007/10/02)
The reactions of substituted phenolate anions with m-nitrophenyl, p-nitrophenyl, and 3,4-dinitrophenyl formates follow nonlinear Br?nsted-type correlations that might be taken as evidence for a change in the rate-limiting step of a reaction that proceeds through a tetrahedral addition intermediate. However, the correlation actually represents two different Br?nsted lines that are defined by meta- and para-substituted phenolate anions and by meta- and para-substituted o-chlorophenolate anions. A concerted mechanism for both acetyl- and formyl-transfer reactions is supported by the absence of a detectable change in the Br?nsted slope at ΔpK = 0 for the attacking and leaving phenolate anions within each class of Br?nsted correlations. Regular increases in the dependence of log k on the pKa of the nucleophile with increasing pKa of the leaving group correspond to a positive interaction coefficient pxy = ?β1g/?(pKnuc) = ?βnuc/?(pK1g). The observation of two different Br?nsted lines for the reactions of substituted phenolate anions with phenyl acetates is attributed to a steric effect that decreases the rate of reaction of substituted o-chlorophenolate anions by 25-50%. The reactions of meta- and para-substituted phenolate and o-chlorophenolate anions with substituted phenyl acetate esters follow values of βnuc = 0.53-0.66 and -β1g = 0.50-0.63. The reactions of meta- and para-substituted phenolate anions with formate esters are ～ 103 times faster and follow smaller values of βnuc = 0.43-0.64 and -β1g = 0.31-0.48. However, the reactions of meta- and para-substituted o-chlorophenolate anions with the same formate esters follow larger values of βnuc = 0.63-0.90 and -β1g = 0.46-0.90. The large values of βnuc and -β1g for the reactions of substituted o-chlorophenolate anions with formate esters may arise from destabilization by the o-chloro group of a stacking interaction that is present in the transition state for reactions of formate esters, but not acetate esters.
